Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
S-8
Registration of securities for employees
29 Mar 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
S-3ASR
Automatic shelf registration
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
11 Mar 24
EFFECT
Notice of effectiveness
5 Feb 24
CORRESP
Correspondence with SEC
31 Jan 24
UPLOAD
Letter from SEC
31 Jan 24
D
$125.00 mm in equity, sold $125.00 mm, 10 investors
30 Jan 24
S-3
Shelf registration
26 Jan 24
8-K
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
22 Jan 24
8-K
Results of Operations and Financial Condition
9 Jan 24
EFFECT
Notice of effectiveness
29 Dec 23
CORRESP
Correspondence with SEC
26 Dec 23
UPLOAD
Letter from SEC
22 Dec 23
S-3
Shelf registration
15 Dec 23
8-K
Other Events
11 Dec 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
6 Nov 23
8-K
Other Events
23 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
10 Aug 23
D
Exempt offering of security
5 Jul 23
8-K
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing
27 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
10-Q
2023 Q1
Quarterly report
8 May 23
8-K
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
8 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
8-K
Amendments to Articles of Incorporation or Bylaws
24 Mar 23
S-8
Registration of securities for employees
16 Mar 23
10-K
2022 FY
Annual report
16 Mar 23
8-K
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
16 Mar 23
8-K
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
9 Jan 23
8-K
Other Events
21 Dec 22
424B5
Prospectus supplement for primary offering
21 Dec 22
Latest ownership filings
SC 13G/A
FMR LLC
11 Mar 24
4
Jacob Chacko
8 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
ALKEON CAPITAL MANAGEMENT LLC
13 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Jacob Chacko
8 Feb 24
SC 13G/A
BlackRock Inc.
7 Feb 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
6 Feb 24
144
Notice of proposed sale of securities
6 Feb 24
SC 13G
Venrock Healthcare Capital Partners III, L.P.
1 Feb 24
SC 13G
VIKING GLOBAL INVESTORS LP
30 Jan 24
SC 13G
BlackRock Inc.
29 Jan 24
SC 13G
Frazier Life Sciences Public Fund, L.P.
25 Jan 24
4
Pratik S Multani
3 Jan 24
4
Dominic Piscitelli
3 Jan 24
4
Jacob Chacko
3 Jan 24
4
Pratik S Multani
19 Dec 23
4
Dominic Piscitelli
19 Dec 23
4
Jacob Chacko
19 Dec 23
4
Jacob Chacko
11 Jul 23
4
Jacob Chacko
7 Jul 23
SC 13G
Nextech Crossover I GP S.a r.l.
7 Jul 23
144
Notice of proposed sale of securities
5 Jul 23
4
Jacob Chacko
28 Jun 23
144
Notice of proposed sale of securities
26 Jun 23
4
Angie You
15 Jun 23
4
Lori Anne Kunkel
15 Jun 23
4
Steven L. Hoerter
15 Jun 23
4
Richard A. Heyman
15 Jun 23
4
Mardi Dier
15 Jun 23
SC 13G
Prosight Management, LP
12 Jun 23
4/A
Pratik S Multani
17 Feb 23
4/A
Dominic Piscitelli
17 Feb 23
4/A
Jacob Chacko
17 Feb 23
SC 13G/A
ALKEON CAPITAL MANAGEMENT LLC
13 Feb 23
SC 13G/A
EcoR1 Capital, LLC
10 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G/A
VICTORY CAPITAL MANAGEMENT INC
6 Feb 23